• 1
    Chou R, Croswell JM, Dana T et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762771
  • 2
    Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 13101319
  • 3
    Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13201328
  • 4
    Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol 2009; 181: 16151621
  • 5
    Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311318
  • 6
    Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011; 342: d1539
  • 7
    Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012; 157: 120134
  • 8
    AUA. AUA Disputes Panel's Recommendation on Prostate Cancer Screening. Atlanta: American Urological Association, 2012. Available at: Accessed June 2012
  • 9
    Basch E, Oliver TK, Vickers A et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30: 30203025
  • 10
    Carter HB, Albertsen PC, Barry MJ et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190: 419426
  • 11
    Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 22322241
  • 12
    Wolf AM, Wender RC, Etzioni RB et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 7098
  • 13
    Kawachi MH, Bahnson RR, Barry M et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010; 8: 240262
  • 14
    Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981990
  • 15
    Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000; 283: 32173222
  • 16
    Colbert JA, Adler JN. Clinical decisions. Prostate cancer screening – polling results. N Engl J Med 2012; 367: e25
  • 17
    D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med 2012; 367: e11
  • 18
    Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol 2009; 181: 16221627
  • 19
    Jang TL, Bekelman JE, Liu Y et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 440450
  • 20
    Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50: 11291136
  • 21
    Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res 2001; 35: 13471355
  • 22
    Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011; 29: 17361743
  • 23
    Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307: 16921694
  • 24
    Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male medicare beneficiaries. Arch Intern Med 2012; 172: 16011603
  • 25
    Pollack CE, Noronha G, Green GE, Bhavsar NA, Carter HB. Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med 2012; 172: 668670
  • 26
    Catalona WJ, D'Amico AV, Fitzgibbons WF et al. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012; 157: 137138
  • 27
    Carlsson S, Vickers AJ, Roobol M et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012; 30: 25812584
  • 28
    Miller DC, Hollenbeck BK. Missing the mark on prostate-specific antigen screening. JAMA 2011; 306: 27192720
  • 29
    Schroder FH. Stratifying risk – the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 2011; 365: 19531955